Derivation of Rapamycin: Adventures in Natural Product Chemistry
The macrolide rapamycin ( 1 ) was first described as an antifungal agent in 1975. Even though its biological target and the molecular details were yet to be discovered, rapamycin attracted our interest in the early 90s based on its reported immunosuppressive activity in transplantation
models and based on findings that its mechanism of action was different from those of the known immunosuppressive agents ciclosporin and FK506. In this review we describe our efforts to chemically modify this complex and chemically very sensitive natural product. Despite the limitations regarding
the reaction conditions compatible with rapamycin we discovered ways of selectively modifying specific functional groups. This allowed us, among others, to improve the stability of the parent molecule towards ring-opening. Our efforts culminated in the discovery and development of the 40-O-alkylated
derivative everolimus 2 which became a useful drug in solid organ transplantation, in various cancer indications and as the active principle of the market leading drug-eluting stent.
No Supplementary Data.
No Article Media
Document Type: Research Article
Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland; Captor Therapeutics, 54-427 Wroclaw, Poland
Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland
August 1, 2019
More about this publication?
International Journal for Chemistry and Official Membership Journal of the Swiss Chemical Society (SCS) and its Divisions
CHIMIA, a scientific journal for chemistry in the broadest sense, is published 10 times a year and covers the interests of a wide and diverse readership. Contributions from all fields of chemistry and related areas are considered for publication in the form of Review Articles and Notes. A characteristic feature of CHIMIA are the thematic issues, each devoted to an area of great current significance.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Information for Advertisers
- Ingenta Connect is not responsible for the content or availability of external websites